F
Frank J. Lebeda
Researcher at United States Department of the Army
Publications - 34
Citations - 895
Frank J. Lebeda is an academic researcher from United States Department of the Army. The author has contributed to research in topics: Clostridium botulinum & Neurotoxin. The author has an hindex of 15, co-authored 33 publications receiving 815 citations.
Papers
More filters
Journal ArticleDOI
Decay-accelerating factor limits hemorrhage-instigated tissue injury and improves resuscitation clinical parameters.
Jurandir J. Dalle Lucca,Yansong Li,Milomir Simovic,Jessica L. Slack,Andrew P. Cap,Michael J. Falabella,Michael A. Dubick,Frank J. Lebeda,George C. Tsokos +8 more
TL;DR: DAF improved survival and reduced early Hextend fluid resuscitation requirements in swine subjected to hemorrhagic shock, attributed to decreased complement deposition and limited organ damage.
Journal ArticleDOI
Differential regulation of oxidative burst by distinct β-glucan-binding receptors and signaling pathways in human peripheral blood mononuclear cells
Nandita Bose,Lindsay R. Wurst,Anissa S.H. Chan,Christine M. Dudney,Megan L LeRoux,Michael E. Danielson,Will Paul M,Sonja E Nodland,Myra L. Patchen,Jurandir J. Dalle Lucca,Frank J. Lebeda,John P. Vasilakos +11 more
TL;DR: The hypothesis that human PBMC, specifically monocytes, utilize distinct receptors and overlapping, but distinct, signaling pathways for the oxidative burst in response to challenge by different physical forms of β-glucan is supported.
Journal ArticleDOI
Onset dynamics of type A botulinum neurotoxin-induced paralysis.
TL;DR: The hypothesis that mathematical models having a minimal number of reactions and reactants can simulate published data concerning the onset of paralysis of skeletal muscles induced by BoNT/A at the isolated rat neuromuscular junction (NMJ) and in other systems is tested.
Journal ArticleDOI
Temporal characteristics of botulinum neurotoxin therapy.
TL;DR: It is hypothesize that the combination of this computer-intensive approach with mathematical modeling will predict the percentage of patients who will favorably or adversely respond to this treatment and thus will eventually assist in developing the increasingly important area of personalized medicine.
Patent
Antibodies against type a botulinum neurotoxin
TL;DR: Antibodies for binding epitopes of BoNT/A and hybridomas which produce such antibodies are described in this paper, where the antibodies can be used in a method for detecting BoNT /A in a sample and/or for purifying Bo /A from an impure solution.